By elucidating the interplay of ChREBP with metabolic reprogramming, insulin signaling, and critical pathways, such as AKT/mTOR and Ras/MAPK, our findings pave the way for innovative therapeutic strategies against HCC. Here, MLXIPL is linked to hepatocellular carcinoma.